Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

University of Michigan Rogel Cancer Center

1500 East Medical Center Drive, Ann Arbor, MI 48109 - USA

The University of Michigan Rogel Cancer Center was founded in 1986; it received its NCI designation as a cancer center in 1988 and its comprehensive designation in 1991. The Center is also a founding member of the National Comprehensive Cancer Network. The Rogel Cancer Center brings together in one place more than 400 scientists and clinicians in multidisciplinary teams devoted to cancer research and patient care.

The Rogel Cancer Center has a distinguished history of scientific excellence, collaboration and impact in basic science, clinical research and cancer control research. Through our focus on team science and research excellence, we are advancing knowledge in prevention, early diagnosis, optimal treatment and survivorship care for those at risk of or affected by cancer. Our mission is to reduce cancer burden and improve cancer outcomes through research, innovation, collaboration, education, outreach and engagement.

Clinical research teams include: biomedical prevention and genetics; bone marrow transplant, breast oncology; childhood cancer; connective tissue oncology; cutaneous oncology; experimental therapeutics; gastrointestinal oncology; genitourinary oncology; gynecologic oncology; head and neck oncology and endocrine malignancies; hematologic malignancies; neurologic oncology; and thoracic oncology. We also have a strong focus on outcomes and disparities research.

With members from 53 departments across 9 top-ranked University of Michigan schools, we are harnessing the power of one of the largest, most robust and highly esteemed research universities in the world to create new knowledge about cancer.

As part of Michigan Medicine, the Rogel Cancer Cancer offers multidisciplinary clinics in 24 different cancer types. In each of these clinics, specialized physicians, including dedicated pathologists and radiologists, collaborate to provide comprehensive care for each patient. We take the same approach when supporting patients during treatment. Cancer specialists in psychology, social work, art therapy, nutrition, finance and countless other areas are an integral part of patients’ care team. Michigan’s teams of physicians and nurses work with colleagues in local communities to provide ongoing care for cancer patients and their families. Risk evaluations, genetic counseling, and fertility counseling are also provided.

Website: University of Michigan Rogel Cancer Center

Contact:
Mathew Innes, BSE, MBA
734-763-4073

Trials at this location:

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Status: Open to Accrual
Read More

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Status: Open to Accrual
Read More

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

Status: Open to Accrual
Read More

HCRN-LYM21-544

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms 

Status: Open to Accrual
Read More

HCRN-LYM21-546

A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas

Status: Open to Accrual
Read More

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Status: Open to Accrual
Read More

HCRN-ESO17-325

A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Status: Closed to Accrual
Read More